BLCM Quote, Trading Chart, Bellicum Pharmaceuticals Inc.
home / stock / blcm / blcm quote
$3.48 Last:
4.19% Change Percent:
$3.31 Open:
$3.48 Previous Close:
$3.48 High:
$3.29 Low:
126,132 Volume:
06/24/2021 04:41:36 am Last Trade Date Time:
Quotes are delayed by 15 to 20 minutes.
BLCM Last Five Trading Days
| Stock Date | Open Price | Close Price | High | Low | Volume |
|---|---|---|---|---|---|
| 2021-06-24 | 3.31 | 3.48 | 3.48 | 3.29 | 126,132 |
| 2021-06-23 | 3.15 | 3.34 | 3.35 | 3.15 | 63,842 |
| 2021-06-22 | 3.22 | 3.18 | 3.23 | 3.05 | 150,958 |
| 2021-06-21 | 3.28 | 3.21 | 3.28 | 3.09 | 102,270 |
| 2021-06-18 | 3.19 | 3.27 | 3.4399 | 3.18 | 281,901 |
| 2021-06-17 | 3.1 | 3.18 | 3.21 | 3.05 | 154,317 |
| 2021-06-16 | 3.03 | 3.11 | 3.13 | 2.95 | 148,218 |
| 2021-06-15 | 3.35 | 3.05 | 3.35 | 3.0176 | 267,259 |
| 2021-06-14 | 3.35 | 3.34 | 3.44 | 3.25 | 114,212 |
| 2021-06-11 | 3.4 | 3.29 | 3.4 | 3.22 | 98,051 |
| 2021-06-10 | 3.35 | 3.39 | 3.48 | 3.23 | 119,433 |
| 2021-06-09 | 3.18 | 3.34 | 3.5 | 3.18 | 423,587 |
| 2021-06-08 | 3.06 | 3.18 | 3.19 | 2.95 | 217,521 |
| 2021-06-07 | 2.862 | 3 | 3.18 | 2.83 | 161,798 |
| 2021-06-04 | 2.92 | 2.94 | 3 | 2.89 | 115,214 |
| 2021-06-03 | 3.01 | 2.92 | 3.02 | 2.85 | 116,127 |
| 2021-06-02 | 2.91 | 3.02 | 3.04 | 2.86 | 161,633 |
| 2021-06-01 | 3 | 2.86 | 3.0187 | 2.86 | 151,615 |
| 2021-05-31 | 2.92 | 2.98 | 3.09 | 2.92 | 125,139 |
| 2021-05-28 | 2.92 | 2.98 | 3.09 | 2.92 | 125,139 |
Bellicum Pharmaceuticals Inc. Company Name:
BLCM Stock Symbol:
NASDAQ Market:
Bellicum Pharmaceuticals Inc. Website:
News, Short Squeeze, Breakout and More Instantly...
-
HOUSTON, May 17, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial results for the first quarter 2021 and provided an operational update. “In the firs...
-
Enrolled first patient in Phase 1/2 clinical trial for BPX-603 in solid tumors that express HER2 Clinical hold lifted on Phase 1/2 dose-escalation trial evaluating BPX-601 and rimiducid in patients with previously treated metastatic prostate or pancreatic cancer Conferen...
-
HOUSTON, March 23, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced it will report financial results for the fourth quarter and full year 2020 after the close of U.S. marke...